Literature DB >> 7691636

Differential regulation of the expression of CD38 and human leukocyte antigen-DR on CD34+ hematopoietic progenitor cells by interleukin-4 and interferon-gamma.

H W Snoeck1, F Lardon, M Lenjou, G Nys, D R Van Bockstaele, M E Peetermans.   

Abstract

We studied the effects of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) on the expression of CD38 and human leukocyte antigen (HLA)-DR on purified CD34+ bone marrow progenitor cells. CD34+CD38- and CD34+HLA-DR- cells are largely nonoverlapping populations. After culture for 4 days in IFN-gamma, the expression of CD38 and HLA-DR is significantly increased and the disappearance of the CD38- and HLA-DR- populations is virtually complete. Moreover, IFN-gamma induces a population of CD34+ cells with a very high expression of CD38 (CD34+CD38++ cells), which were absent in the initial CD34+ population. IL-4 has no effect on the expression of CD38, but induces a limited but significant increase in the expression of HLA-Dr. After culture in IFN-gamma, CD34+ cells show a higher cloning efficiency of the colony-forming unit-macrophage (CFU-M) and burst-forming unit-erythroid (BFU-E) compared to cells cultured in medium alone. After culture in IL-4, a limited increase in CFU-granulocyte (CFU-G) and BFU-E is seen, whereas CFU-G, CFU-M, and BFU-E are increased after culture in IL-4 plus IFN-gamma. We further investigated the functional properties of the CD34+CD38++ cells generated in the presence of IFN-gamma. This cell population is highly enriched for BFU-E but partially depleted of CFU-M. Most of the CFU-M were found in the CD34+CD38+/-(CD34+CD38- and CD34+CD38+ cells) population.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691636

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

Review 1.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

Review 2.  IFN-γ and CD38 in Hyperprogressive Cancer Development.

Authors:  Stefania Angelicola; Francesca Ruzzi; Lorena Landuzzi; Laura Scalambra; Francesco Gelsomino; Andrea Ardizzoni; Patrizia Nanni; Pier-Luigi Lollini; Arianna Palladini
Journal:  Cancers (Basel)       Date:  2021-01-15       Impact factor: 6.639

Review 3.  Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.

Authors:  Hao-Tian Wu; Xiang-Yu Zhao
Journal:  Int J Biol Sci       Date:  2022-02-21       Impact factor: 6.580

4.  Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells.

Authors:  H W Snoeck; D R Van Bockstaele; G Nys; M Lenjou; F Lardon; L Haenen; I Rodrigus; M E Peetermans; Z N Berneman
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

Review 5.  NK cells and CD38: Implication for (Immuno)Therapy in Plasma Cell Dyscrasias.

Authors:  Renato Zambello; Gregorio Barilà; Sabrina Manni; Francesco Piazza; Gianpietro Semenzato
Journal:  Cells       Date:  2020-03-21       Impact factor: 6.600

6.  Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth.

Authors:  Xun Ma; Sandy W Wong; Ping Zhou; Chakra P Chaulagain; Parul Doshi; Andreas K Klein; Kellie Sprague; Adin Kugelmass; Denis Toskic; Melissa Warner; Kenneth B Miller; Lisa Lee; Cindy Varga; Raymond L Comenzo
Journal:  Exp Hematol Oncol       Date:  2018-10-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.